Litcius/Paper detail

Lateral Flow Immunoassay with Quantum-Dot-Embedded Silica Nanoparticles for Prostate-Specific Antigen Detection

Sungje Bock, Hyung‐Mo Kim, Jaehi Kim, Jaehyun An, Yun-Sik Choi, Xuan‐Hung Pham, Ahla Jo, Kyeong-Min Ham, Hobeom Song, Jungwon Kim, Eunil Hahm, Won‐Yeop Rho, Sang Hun Lee, Seung Min Park, Sangchul Lee, Dae Hong Jeong, Ho‐Young Lee, Bong‐Hyun Jun

2021Nanomaterials54 citationsDOIOpen Access PDF

Abstract

Prostate cancer can be detected early by testing the presence of prostate-specific antigen (PSA) in the blood. Lateral flow immunoassay (LFIA) has been used because it is cost effective and easy to use and also has a rapid sample-to-answer process. Quantum dots (QDs) with very bright fluorescence have been previously used to improve the detection sensitivity of LFIAs. In the current study, a highly sensitive LFIA kit was devised using QD-embedded silica nanoparticles. In the present study, only a smartphone and a computer software program, ImageJ, were used, because the developed system had high sensitivity by using very bright nanoprobes. The limit of PSA detection of the developed LFIA system was 0.138 ng/mL. The area under the curve of this system was calculated as 0.852. The system did not show any false-negative result when 47 human serum samples were analyzed; it only detected PSA and did not detect alpha-fetoprotein and newborn calf serum in the samples. Additionally, fluorescence was maintained on the strip for 10 d after the test. With its high sensitivity and convenience, the devised LFIA kit can be used for the diagnosis of prostate cancer.

Topics & Concepts

Detection limitImmunoassayProstate cancerQuantum dotMaterials scienceSensitivity (control systems)Prostate-specific antigenNanoparticleBiomedical engineeringChromatographyNanotechnologyCancerChemistryMedicineImmunologyInternal medicineAntibodyElectronic engineeringEngineeringBiosensors and Analytical DetectionProstate Cancer Diagnosis and TreatmentAdvanced biosensing and bioanalysis techniques